Yanli Xiong

Title: Yanli Xiong: Innovator in Drug Modification Technologies

Introduction

Yanli Xiong is a prominent inventor based in Beijing, China. He has made significant contributions to the field of drug modification technologies, holding a total of four patents. His work focuses on enhancing the efficacy and bioavailability of drugs through innovative chemical conjugates.

Latest Patents

Yanli Xiong's latest patents include a linker compound, polyethylene glycol-linker conjugate and derivative thereof, and polyethylene glycol-linker-drug conjugate. These inventions disclose a linker compound that can modify drugs, simplifying the modification reaction while achieving high yields. The modified drugs are designed to degrade gradually in vivo, allowing them to remain at targeted sites, such as cancer lesions, for extended periods. This approach aims to provide sustained and controlled drug release, reduce administration frequency, and significantly improve patient compliance.

Another notable patent is the multi-arm multi-claw polyethylene glycol derivative suitable for click chemistry reactions. This invention features a general formula that includes various structural configurations of polyethylene glycol residues, linking groups, and terminal groups. This versatility enhances the potential applications of the derivative in drug development.

Career Highlights

Yanli Xiong has worked with Jenkem Technology Co., Ltd. in both Tianjin and Beijing. His experience in these companies has allowed him to further develop his innovative ideas and contribute to advancements in drug modification technologies.

Collaborations

Throughout his career, Yanli has collaborated with notable colleagues, including Zewang Feng and Jinliang Wang. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the field.

Conclusion

Yanli Xiong is a distinguished inventor whose work in drug modification technologies has the potential to revolutionize treatment options for patients. His innovative patents reflect a commitment to improving drug efficacy and patient compliance.